Axsome Therapeutics, Inc. (AXSM) company profile
Close on Nov 17, 2026Market cap $7.12BP/E –Yield –
About Axsome Therapeutics
Pharmaceutical Preparations, SIC 2834
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes novel therapies for central nervous system conditions. The company’s commercial offerings include AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness related to obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute migraine treatment. Axsome also advances an investigational pipeline addressing psychiatric and neurological indications, including AXS-05 for Alzheimer’s disease agitation and smoking cessation, solriamfetol for conditions such as attention deficit hyperactivity disorder, and late-stage candidates for narcolepsy and fibromyalgia. Its products primarily serve adult patients diagnosed with these targeted medical conditions.
The company retains commercial rights within the United States and engages in licensing partnerships to market products internationally. Its commercial reach outside the U.S. includes distribution in Europe and selected territories across the Middle East and North Africa through a partner agreement. Axsome Therapeutics maintains its principal executive offices at One World Trade Center in New York, New York.
Summary of the business section of Axsome Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Axsome Therapeutics, Inc.
- Founded
- 2012
- Headquarters
- New York, NY
- Address
- One World Trade Center, 29th Floor 10007
- Phone
- (212) 332-3241
- Website
- axsome.com
- Employees
- 500, Dec 31, 2017
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Morristown, New Jersey
Stock & identifiers
- Ticker
- AXSM
- Exchange
- Nasdaq
- IPO date
- Nov 19, 2015
- Shares outstanding
- 52M, Aug 3, 2026
- Public float
- $4.40B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1579428
- CUSIP
- 05464T104
- ISIN
- US05464T1043
- FIGI
- BBG00B6G7GL7
- Share class FIGI
- BBG00B6G7GM6
- LEI
- 549300EXGR0XLRJEIB95
- EIN
- 45-4241907
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Herriot Tabuteau | Chief Executive Officer, Director | 7,356,389 |
| Mark L. Jacobson | Chief Operating Officer | 10,000 |
| Nick Pizzie | Chief Financial Officer | 43,355 |
| Ari Maizel | Chief Commercial Officer | 7,500 |
| Hunter R. Murdock | General Counsel | 6,014 |
| Roger Jeffs | Director | 105,279 |
| Mark Coleman | Director | 434,245 |
| Susan Mahony | Director | 829 |
| Mark E. Saad | Director | 11,731 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $10.28M | $33.80M | $3.59M | $224 | $125 |
| FY2024 | $10.36M | $10.06M | $3.61M | $104 | $93 |
| FY2023 | $9.90M | $9.64M | $3.55M | $98 | $94 |
| FY2022 | $8.32M | $28.01M | $3.20M | $95 | $90 |
| FY2021 | $8.05M | -$11.12M | $4.51M | $46 | $100 |
| FY2020 | $7.30M | $1.83M | $2.40M | $79 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Herriot Tabuteau Chief Executive Officer, President and Chairman of the Board | $835.00K | $5.53M | $2.83M | $876.75K | $204.95K | $10.28M | -1% |
| Nick Pizzie Chief Financial Officer | $530.00K | $1.82M | $933.33K | $358.00K | $86.59K | $3.73M | -1% |
| Mark Jacobson Chief Operating Officer | $575.00K | $2.08M | $1.07M | $388.00K | $95.57K | $4.21M | -1% |
| Hunter Murdock General Counsel | $530.00K | $1.50M | $766.59K | $358.00K | $72.64K | $3.22M | -1% |
| Ari Maizel Chief Commercial Officer | $530.00K | $1.50M | $766.59K | $358.00K | $36.99K | $3.19M | -0% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 19, 2015
- Offer price
- $9.00
- Securities offered
- 5,666,667
- Gross proceeds
- $51.00M
- Exchange
- Nasdaq
- First trading day
- Nov 19, 2015
- First-day close
- $8.74-2.9%
- Lock-up ends (est.)
- May 17, 2016
“The initial public offering price is $9.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 26, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 14, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 9, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 19, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 16, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?